Market Intelligence

Access the latest earnings reports, market analysis, hot topics, and individual stock insights

Report Categories

View All

Recent Articles

View All
Lloyds LYG Stock Variable Dividend Institutional Selling 20260420 Vertex Pharmaceuticals VRTX Fundamental Outlook Amid Recent Retail Investor Interest What Jack Henry JKHY is doing to earn customer loyalty Weakens 20260511 Merck Co Inc MRK Shares Underperform Broader Market Ahead of Q1 2026 Earnings Release Newmont Corporation NEM National Bank Downgrade Reflects NearTerm Headwinds Amid Broad Bullish LongTerm Consensus What Ibotta IBTA is doing to expand margins Ibotta reports 292 EPS miss vs analyst estimates Regeneron Pharmaceuticals REGN Bullish Investment Case Strengthens Post FDA Hearing Gene Therapy Approval Amid Temporary Share Pullback OpenAI Governance Trial AI Sector and Investment Implications UMHD UMH quarterly earnings carry no comparable financial metrics as investors await further performance disclosures Black Stone BSM Rallies 071 as Bulls Target 1487 20260519 DigitalAsset DAAQ Stalls at 1031 Breakout or Breakdown 20260519 Reddit RDDT Q1 2026 Earnings Beat Revenue NA EPS 101 Kura Oncology KURA Drops 534 Key Support at 876 20260517 DeFi Development Corp Warrant DFDVW Falls Over 11 as Price Approaches Key Support at 050 Nexxen International NEXN Q3 2025 Earnings Surprise EPS 020 Up Significant Cronos CRON Stock Jumps 172 Approaching 278 20260520 Masimo Corporation MASI Holds 17881 Direction Awaited 20260520 VLGEA Q1 2025 Earnings EPS of 086 Reported Shares Edge Lower Amid Sparse Data SKM Q4 2025 Earnings EPS Misses Estimates Stock Declines MT Bank MTB Q1 2026 Earnings EPS Beat Amidst Stable Loan Activity Acadian Asset Management Inc AAMI Q1 2026 Earnings Strong EPS Beat Signals Resilience in Volatile Markets LPA Q1 2026 Earnings Negative EPS of 025 Amid Unreported Revenue Stock Falls 74 Polyrizon Ltd PLRZ Surges Over 20 Key Resistance Level in Focus Gilat Satellite Networks GILT Edges Higher as Shares Test Key Resistance Aditxt Inc ADTX Plunges Over 57 as Selling Pressure Intensifies Structure Therapeutics GPCR Posts Marginal Decline Eyes Key Support Levels